ATE248511T1 - Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung - Google Patents

Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung

Info

Publication number
ATE248511T1
ATE248511T1 AT97915020T AT97915020T ATE248511T1 AT E248511 T1 ATE248511 T1 AT E248511T1 AT 97915020 T AT97915020 T AT 97915020T AT 97915020 T AT97915020 T AT 97915020T AT E248511 T1 ATE248511 T1 AT E248511T1
Authority
AT
Austria
Prior art keywords
composition
medication
therapeutic
agents
targeted sites
Prior art date
Application number
AT97915020T
Other languages
English (en)
Inventor
Thomas R Porter
Patrick L Iversen
Gary D Meyer
Original Assignee
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska filed Critical Univ Nebraska
Application granted granted Critical
Publication of ATE248511T1 publication Critical patent/ATE248511T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT97915020T 1996-03-12 1997-03-12 Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung ATE248511T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61549596A 1996-03-12 1996-03-12
PCT/US1997/003876 WO1997033474A1 (en) 1996-03-12 1997-03-12 Targeted site specific drug delivery compositions and method of use

Publications (1)

Publication Number Publication Date
ATE248511T1 true ATE248511T1 (de) 2003-09-15

Family

ID=24465630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97915020T ATE248511T1 (de) 1996-03-12 1997-03-12 Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung

Country Status (7)

Country Link
EP (1) EP0888054B1 (de)
JP (1) JP2007297414A (de)
AT (1) ATE248511T1 (de)
AU (1) AU725693B2 (de)
CA (1) CA2248158A1 (de)
DE (1) DE69724599T2 (de)
WO (1) WO1997033474A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849727A (en) 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
BR9712683A (pt) 1996-10-28 1999-10-19 Nyomed Imaging A S Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente.
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1998018501A2 (en) * 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
EP0991427A2 (de) * 1996-10-28 2000-04-12 Marsden, John Christopher Verbesserungen an oder in verbindung mit diagnostischen/therapeutischen mitteln
DE69911777T2 (de) * 1998-07-13 2004-04-29 University Of Nebraska Board Of Regents, Lincoln Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
GB9917416D0 (de) * 1999-07-23 1999-09-22 Univ Ulster
DE10108798A1 (de) * 2001-02-19 2002-09-26 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur ultraschallgestützten transmembranen Medikamentenapplikation in vivo
WO2003043663A1 (fr) * 2001-11-22 2003-05-30 Anges Mg, Inc. Preparations inhibant le rejet dans la transplantation d'organe et son procede d'utilisation
US20050147589A1 (en) * 2002-03-22 2005-07-07 Ryuuichi Morishita Compositions for delivering biologically active drug and method of using the same
US8715221B2 (en) 2006-03-08 2014-05-06 Fresenius Medical Care Holdings, Inc. Wearable kidney
US8012118B2 (en) 2006-03-08 2011-09-06 Fresenius Medical Care Holdings, Inc. Artificial kidney dialysis system
KR101419682B1 (ko) 2006-08-24 2014-07-17 프레제니우스 메디칼 케어 홀딩스 인코퍼레이티드 환자의 혈액으로부터 유체를 제거하는 장치
US8454937B2 (en) 2006-09-12 2013-06-04 Temple University—Of The Commonwealth System of High Education Method and composition for the site-selective delivery using viruses encapsulated in microbubbles
MX2011004631A (es) 2008-11-03 2011-06-17 Fresenius Med Care Hldg Inc Sistema de dialisis peritoneal portatil.
US20130072854A1 (en) * 2011-09-19 2013-03-21 General Electric Company Microbubble complexes and methods of use
WO2014117232A1 (pt) * 2013-02-04 2014-08-07 Farret Neto Abdo Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504340B1 (de) * 1990-10-05 1995-06-21 BRACCO International B.V. Verfahren zur herstellung von stabilen suspensionen von hohlen mit gasgefüllten mikrosphären zur verwendung in ultraschallechographie
CA2063529A1 (en) * 1991-03-22 1992-09-23 Katsuro Tachibana Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US5648098A (en) * 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
DE69738406T2 (de) * 1996-10-21 2008-12-04 Ge Healthcare As Verbesserungen in oder an Kontrastmitteln

Also Published As

Publication number Publication date
CA2248158A1 (en) 1997-09-18
DE69724599D1 (de) 2003-10-09
WO1997033474A1 (en) 1997-09-18
AU2207197A (en) 1997-10-01
EP0888054A4 (de) 1999-04-28
DE69724599T2 (de) 2004-08-05
EP0888054A1 (de) 1999-01-07
JP2007297414A (ja) 2007-11-15
AU725693B2 (en) 2000-10-19
EP0888054B1 (de) 2003-09-03

Similar Documents

Publication Publication Date Title
ATE260677T1 (de) Zusammenstellungen und verfahren zur änderung der bioverteilung von biologischen agentien
DE69724599D1 (de) Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ATE533493T1 (de) Schäumende pharmazeutische zusammensetzungen und verfahren zur behandlung einer erkrankung
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
ATE292982T1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten
TW200612987A (en) Combination treatment for non-hematologic malignancies
ATE357214T1 (de) Verwendung eines unverkapselten anti-krebs- wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation
ATE419836T1 (de) Manipulationssichere dosierform mit einem adsorbens und einem adversen mittel
ATE259226T1 (de) Zusammmensetzungen und verfahren zur verminderung der atmungsdepressionen und begleitender nebenmwirkungen von mu-opioid-verbindungen
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
MX2009003737A (es) Composicion inyectable en deposito y su procedimiento de preparacion.
JP2005506995A5 (de)
DE69730988D1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR0315593A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
ATE250940T1 (de) Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
DE69822810D1 (de) Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x
ATE367806T1 (de) Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie
ATE228843T1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0888054

Country of ref document: EP